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Background: The discovery of molecular markers associated with various breast cancer subtypes has greatly
improved the treatment and outcome of breast cancer patients. Unfortunately, breast cancer cells acquire
resistance to various therapies. Mounting evidence suggests that resistance is rooted in the deregulation of the G1
phase regulatory machinery.
Methods: To address whether deregulation of the G1 phase regulatory machinery contributes to radiotherapy
resistance, the MCF10A immortalized human mammary epithelial cell line, ER-PR-Her2+ and ER-PR-Her2- breast
cancer cell lines were irradiated. Colony formation assays measured radioresistance, while immunocytochemistry,
Western blots, and flow cytometry measured the cell cycle, DNA replication, mitosis, apoptosis, and DNA breaks.
Results: Molecular markers common to all cell lines were overexpressed, including cyclin A1 and cyclin D1, which
impinge on CDK2 and CDK4 activities, respectively. We addressed their potential role in radioresistance by
generating cell lines stably expressing small hairpin RNAs (shRNA) against CDK2 and CDK4. None of the cell lines
knocked down for CDK2 displayed radiosensitization. In contrast, all cell lines knocked down for CDK4 were
significantly radiosensitized, and a CDK4/CDK6 inhibitor sensitized MDA-MB-468 to radiation induced apoptosis. Our
data showed that silencing CDK4 significantly increases radiation induced cell apoptosis in cell lines without
significantly altering cell cycle progression, or DNA repair after irradiation. Our results indicate lower levels of
phospho-Bad at ser136 upon CDK4 silencing and ionizing radiation, which has been shown to signal apoptosis.
Conclusion: Based on our data we conclude that knockdown of CDK4 activity sensitizes breast cancer cells to
radiation by activating apoptosis pathways.
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Breast cancer is the most common malignancy and the
major cause of cancer related deaths of women in indus-
trialized countries [1]. Fortunately, the discoveries of vari-
ous biomarkers have greatly improved the treatment of
breast cancer patients [2]. For example, breast cancer pa-
tients that express progesterone receptor (PR) and estrogen
receptor (ER) (luminal A breast cancers are ER+PR+HER2-
or ER+PR+HER2+, while luminal B are ER+PR+HER2-)
are treated with endocrine therapies and/or with the anti-
body Herceptin, in combination with chemotherapy and/or* Correspondence: hsaaved@emory.edu
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reproduction in any medium, provided the orradiotherapy [3]. Regrettably, the defining characteristic of
triple negative breast cancers (a subtype of basal breast
cancers) is the absence of ER, PR and HER2, rendering
those cancers insensitive to some of the most effective
therapies [4]. ER-PR-HER2- and ER-PR-HER2+ patients
show decreased survival relative to luminal subtypes [5,6].
Radiotherapy is one of the cornerstones in the treatment
of patients with breast cancer [7,8]. Radiation greatly re-
duces the risk of recurrence in women with ductal car-
cinoma in situ [9,10] and in breast cancer patients who
are lymph node positive [11-13]. The outcomes follow-
ing chemotherapy vary depending on the subtype: for
example, ER-PR-HER2- and ER-PR-HER2+ breast cancers
respond better than luminal subtypes to anthracycline-
based chemotherapies [14]. In contrast, all subtypes respondLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ER-PR-HER2- or ER-PR-HER2+ breast cancers are more
likely to recur upon breast conserving therapies or fol-
lowing mastectomy and radiation [16-19]. Even though
radiotherapy shows promise in the treatment of all breast
cancer subtypes, radiotherapy is associated with increased
risk of cardiovascular disease [20]. In addition, breast tu-
mors can acquire radioresistance [21,22]. Finding agents
that sensitize malignant cells to radiation would increase
tumor response while minimizing toxicity to surrounding
organs by lowering effective therapeutic doses.
The G1/S phase regulatory machinery includes cyclins
and cyclin kinase inhibitors (CKIs) that regulate the
activities of the G1 phase CDKs [23,24] and the Rb/E2F
pathway [25,26]. Besides being distinguished by their ER,
PR, or Her2 status, the various breast cancer subtypes
exhibit deregulated expression of proteins that ensure
progression through the G1/S phase of the cell cycle.
ER-PR-HERr2- breast cancers are more likely to overexpress
mutant p53, E2F3, p16, and cyclin E and display lower
levels of cyclin D1, Bcl2, and Rb relative to other breast
cancer subtypes [5,6,27,28]. Cyclin D1 overexpression is
more often found in tumors with wild type p53, higher
grades of differentiation, and expression of ER or PR
[29-32]. Specifically, 53% PR+ and 58% ER+ breast can-
cer patients overexpress cyclin D1, while a smaller, but
significant fraction of ER- and PR- breast cancers (21%
and 31% respectively) overexpress cyclin D1 [33].
Several studies have shown that G1/S phase regulatory
molecules may drive lower survival rates in patients and
resistance to adjuvant therapies. Deregulated expression
of cell cycle molecules that specifically modulate CDK2
kinase activity has been associated with poor prognosis
of breast cancer patients. For example, high cyclin A ex-
pression in metastatic breast cancer correlates significantly
with a shorter time to first relapse and is a prognostic
factor in early stage ER+ breast tumors [34,35]. Addition-
ally, high cyclin E expression predicts a poor prognosis
in breast cancer [36,37]. Unregulated CDK2 activity may re-
sult in poorer survival due to the modulation of responses
to various therapeutic agents. For example, low expression
of p27Kip1 and/or cyclin E overexpression predicts early
relapse in patients treated with adjuvant therapy that
includes tamoxifen [38,39], doxorubicin, cyclophospha-
mide [40], and Herceptin [41]. Increased CDK2 kinase
activity drives Herceptin resistance in vitro and in vivo
[41,42].
Deregulated CDK4/CDK6 activities have also been associ-
ated with decreased survival and resistance to various ther-
apies. Cyclin D1 is overexpressed in over 50% of breast
cancers [43,44]. The oncogenic capacity of cyclin D1/CDK4/
CDK6 in experimental models, including mouse models
of mammary carcinogenesis has been established [45-47].
However, the role of cyclin D1/CDK4/CDK6 in breastcancers is highly controversial. For example, increased
cyclin D1 mRNA and amplification of CCND1 in ER+
breast cancers strongly correlated with increased risk of
relapse, local recurrence, metastasis, and death [30,31,48],
and ER- patients with cyclin D1 overexpression display
shorter overall survival [33]. In contrast, other studies
showed that patients overexpressing cyclin D1 (including
ER+ tumors and unclassified breast tumors not falling
within the canonical HER2, PR, ER classification) were less
likely to recur following treatment and displayed longer
survival [32,49-51]. Similar to cyclins E and A, there is
experimental evidence as to the involvement of cyclin D
in resistance or sensitivity to various therapies. Patients
within the ER+ subgroup who received endocrine therapy
for their primary or recurrent breast cancers showed an
association between high cyclin D1 and a shorter response
duration [30,52,53]. In addition, in vitro studies showed
that overexpressed cyclin D1 leads to resistance to anties-
trogens [54]. While some studies showed that ectopic
cyclin D1 expression is directly involved in radioresistance
and the poor prognosis of various carcinomas after radio-
therapy [55-59], others found that ectopic expression of
cyclin D1 markedly increases cell sensitivity to apoptosis
induced by various agents including ionizing radiation
[60-63]. In addition, chemical inhibition of CDK4 and
CDK6 synergizes with Herceptin and tamoxifen treat-
ments [64].
Although CDK4 and CDK2 are promising targets in
cancer therapeutics, their role in the response of ER-
PR-HER2+ or ER-PR-HER2- breast cancer cells to ioniz-
ing radiation is controversial and not extensively explored.
We present data showing that knockdown of CDK4, but
not of CDK2, imparts radiosensitivity to breast cancer
cells and normal mammary epithelial cells by signaling an
apoptotic program.
Results
G1/S phase regulatory molecules are ectopically
expressed in radioresistant breast cancer cells
While many deregulated signaling pathways, including
PI3K, NFKB, and the MAPK pathways are involved in
signaling radiation resistance [65], the role played by the
G1/S phase regulatory machinery phase in radiation re-
sistance is unclear. The overall hypothesis of this study
is that breast cancer cells are radioresistant because they
harbor deregulated G1/S phase cell cycle machinery. The
controversy regarding the role played by the G1/S
phase regulatory machinery in radioresistance may be
due to the use of normal or transformed cells lines,
their tissue of origin, or to the dose and duration of ra-
diation treatments [55,58-60]. Because of this, we tested
our hypothesis in a non-transformed mammary epithelial
cell line and breast cancer cell lines of various molecular
subtypes, irradiated with increasing, single doses of
AB
C
Figure 1 G1/S phase regulatory molecules are ectopically
expressed in radioresistant breast cancer cells. (A) Non-transformed
human mammary epithelial cells (MCF10A) and ER-PR-HER2- human
breast cancer cell lines (HCC1806, HS578, MDA-MB-231 & MDA-MB-468)
were irradiated at 2 Gy. Western blots of lysates prepared from both
the unirradiated (U) and the irradiated (I) cells were immunoblotted
with anti-cyclin A, anti-cyclin E, anti-p21CIP1 and anti-p27KIP1
antibodies. (B) Western blot analyses of lysates prepared from
various unirradiated human breast cancer cell lines (triple negative
and ER-PR-HeR2+ and MCF10A) were immunoblotted with anti-cyclin
D1 antibody. (C) Lentivirus containing shRNA constructs specific for
CDK2 or CDK4 were used to infect human breast cancer cell lines and
MCF10A cells. A pLKO.1 lentiviral vector containing a randomized
shRNA sequence was used as control. After puromycin selection, the
surviving cells were pooled. The lysates prepared from the infected
cells were immunoblotted with anti-CDK2 or anti-CDK4 antibodies to
confirm the knockdown efficiency. Equal loading was assessed by
immunoblotting with a β-actin antibody.
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(non-transformed, immortalized mammary epithelial
cells lacking the cyclin kinase inhibitors p16INK4A and
p15INK4B due to a homozygous deletion), ER-PR-HER2-
and ER-PR-HER2+ breast cancer cells to form colonies
after increasing single doses of γ-radiation (0, 1, 2, 4, 6, or
8 Gy). Analyses revealed that most of the breast cancer
cell lines tested in this study showed resistance to radi-
ation with a statistically significantly increased IC50
comparing to the immortalized MCF10A cells (Table 1).
To identify mechanisms resulting in radioresistance,
we assessed the relative protein expression of G1/S cell
cycle regulatory molecules that have been shown to as-
sociate with relapse and to impaired responses to various
therapies. We focused on proteins that affect CDK2 or
CDK4 activities, including cyclins A, E, D, p21CIP1, and
p27KIP1 (Figure 1). Western blot analyses showed that
p27KIP1 levels were higher in untreated ER-PR-HER2-
breast cancer cells relative to MCF10A cells and showed
no change upon irradiation (Figure 1A). Levels of cyclin
E were higher in MCF10A cells relative to breast cancer
cells irrespective of irradiation. Other molecules, includ-
ing cyclin A and p21CIP1, were upregulated in both ER-
PR-HER2- and MCF10A cells after irradiation, while
cyclin D1 levels did not change. We measured cyclin D1
levels in non-irradiated MCF10A, ER-PR-HER2-, and
ER-PR- HER2+ cell lines and showed that all breast can-
cer cell lines overexpressed cyclin D1 (Figure 1B).
Because the breast cancer cell lines overexpressed cyc-
lin D1, and cyclin A protein levels were elevated follow-
ing irradiation, we tested whether knockdowns of their
respective kinase partners CDK4 and CDK2 might alter
the relative radioresistance of various breast cancer cell
lines. Therefore, we generated ER-PR-Her2- and MCF10A
cell lines stably expressing shCDK2 or shCDK4. All cell
lines showed consistently stable decreases in the protein level
of CDK2 or CDK4 (Figure 1C). MCF10A and HCC1806
cells displayed complete downregulation of CDK4, while
MDA-MB-468 and MDA-MB-231 cells showed a partial,
but almost complete knockdown of CDK4. In addition,Table 1 IC50 of Irradiation in non-transfected human
breast cell lines
Cell line Cell type
IC50
Est. (SE) P value1
MCF10A Normal 1.54 (0.116) -
MDA-MB-231 ER-PR- HER2- 1.93 (0.191) 0.04
HCC1806 ER-PR- HER2- 1.68 (0.128) 0.398
MDA-MB-468 ER-PR- HER2- 2.06 (0.155) 0.02
HCC1954 ER-PR- HER2+ 2.60 (0.189) <0.001
SKBR3 ER-PR- HER2+ 2.08 (0.156) 0.001
1The p value is based on the comparisons relative to MCF10A group for each
cell line.HCC1806 and MDA-MB-231 cells displayed complete
knockdown of CDK2, while MCF10A and MDA-MB-468
cells displayed a partial, but significant knockdown of
CDK2. Importantly, knockdown of CDK2 did not affect
CDK4 levels and vice versa, demonstrating that specific
knockdowns were achieved. To assess whether silencing
of CDK4 altered radioresistance in other breast cancer
subtypes, we generated HCC1954 and SKBR3 cells
(both ER-PR-HER2+ cell lines) knocked down for CDK4
(Figure 1C). Similarly to ER-PR-HER2- and MCF10A
cells, CDK2 levels in ER-PR-HER2+ cells were not af-
fected by knockdown of CDK4.
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to radiation
After cell lines stably silenced for CDK2 and CDK4 were
established, all cell lines received ionizing radiation at
doses ranging between 0 to 8 Gy. The relative radiosensi-
tivity and the radiation dose that causes a 50% decrease
in the number of colonies (IC50) were calculated using
colony forming assays (Figure 2A, Table 2). Even though
CDK2 has been reported to mediate resistance to various
adjuvant therapies against breast cancers, downregulation
of CDK2 did not alter the sensitivity (IC50) to radiation
in ER-PR-HER2- cells or in MCF10A cells relative to
cells expressing control vector (Figure 2B, Table 2). In
contrast, all cell lines harboring CDK4 knockdown,





























































Figure 2 Downregulated CDK4 sensitizes breast cancer cells to radiat
at single doses of 0, 1, 2, 4, 6, or 8 Gy γ-rays. After an average of 8 days, cel
manually. (A) The figure shows colony formation in MCF10A and ER-PR-HE
with pLKO.1, shCDK2 or shCDK4. ER-PR-Her2+cells were only transfected w
formation relative to unirradiated cells of the respective groups; the x axis
significance are presented in Table 2.showed significantly decreased IC50, meaning that the
ablation of CDK4 in both the normal and tumor cell
lines sensitizes these cells to radiation.
Radiosensitivity imparted by downregulated CDK4 is not
caused by cell cycle blocks
Radioresistance can be a consequence of a deregulated
cell cycle, altered frequencies of apoptosis, or altered fre-
quencies of DNA repair [58-60]. To address whether
radiosensitization occurs because of cell cycle blocks, we
irradiated MCF10A and ER-PR-HER2- cells with 2 Gy
and assessed percentages of proliferating cells using the
BrdU incorporation assay by direct counting using fluor-
escence microscopy (Additional file 1A) and by flow cy-
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ion. Cells stably expressing pLKO.1, shCDK2 or shCDK4 were irradiated
ls were fixed and stained with 1% crystal violet; colonies were counted
R2- cells at 0 and 6 Gy. (B) Survival curves of various cells transfected
ith pLKO.1 or shCDK4. The y axis represents percentage colony
represents the various radiation doses. The IC50 and statistical
Table 2 IC50 of irradiation in breast cancer cell lines with
CDK2 or CDK4 knockdown
Cell line Vector IC50
Est. (SE) P value1
MCF10A pLKO.1 1.76 (0.106) -
shCDK2 1.75 (0.103) 0.943
shCDK4 1.34 (0.076) 0.005
MDA-MB-231 pLKO.1 1.89 (0.141) -
shCDK2 2.15 (0.158) 0.197
shCDK4 1.27 (0.096) 0.003
HCC1806 pLKO.1 1.95 (0.149) -
shCDK2 2.14 (0.173) 0.364
shCDK4 0.85 (0.078) <0.001
MDA-MB-468 pLKO.1 2.04 (0.139) -
shCDK2 2.27 (0.156) 0.252
shCDK4 1.25 (0.093) <0.001
HCC1954 pLKO.1 2.99 (0.301) -
shCDK4 2.02 (0.160) 0.013
1The p value is based on the comparisons with pLKO.1 group within each
cell line.
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http://www.celldiv.com/content/8/1/10marker of proliferation (Additional file 1B). Additional
file 1 represents two preliminary experiments with a
wider range of timepoints, to establish whether DNA
replication was affected up to 48 hours post-irradiation.
Neither BrdU nor Ki-67 immunocytochemistry showed
differences in proliferation in cells downregulated for
CDK4 relative to the control pLKO.1 group. Although
cells expressing shCDK2 incorporated BrdU at a lower
extent than other groups (Additional file 1A), no differences
were found when using Ki67 as an independent marker of
proliferation (Additional file 1B). After establishing that
DNA replication was not affected, a smaller number of
timepoints (0, 6, 12 and 24 hours post-irradiation) were
chosen for final analyses. The relative percentage of cells in
each phase of the cell cycle was assessed by measuring
DNA content using flow cytometry (Figure 3), while a flow
cytometry-based BrdU assay measured percentage of repli-
cating cells post-irradiation (Table 3). The BrdU assay didTable 3 Comparison of BrdU between control (pLKO.1) and tr
Cell line Vector 6 hr
Mean* std P-value† M
MCF10A pLKO.1 5.629 3.740
0.1124
2
shCDK4 2.807 2.460 1
MDA-MB-468 pLKO.1 1.619 0.614
0.7841
1
shCDK4 0.842 0.915 1
MDA-MB-231 pLKO.1 1.698 0.870
0.8941
1
shCDK4 1.806 0.731 2
* Mean (standard deviation) of the fold change to no radiation.
† P-value is for comparing in the mean fold change no radiation between control anot detect significant differences in the percentage of pro-
liferating cells between control and cells silenced for CDK4
(Table 3). Likewise, flow cytometry did not reveal any
major changes in the percentage of cells in G1, S, or
G2/M phases of the cell cycle in irradiated or non-
irradiated cells when comparing shCDK4 cells relative
to pLKO.1 controls (Figure 3). Thus, downregulation of
CDK4 does not radiosensitize cells through compromis-
ing their proliferation capacity.
To measure if knockdown of CDK4 radiosensitizes
cells by signaling mitotic blocks, cells were immuno-
stained for phospho-histone 3 after irradiation. Histone 3
is one of eight core histone proteins that play an im-
portant role in transcription regulation in eukaryotes
through various modifications, including phosphorylation
[66]. Phosphorylation of histone 3 at Ser10, Ser28 and
Thr11 is correlated with chromosome condensation
during mitosis [67,68] and is regarded as an indicator of
mitosis. Overall, no significant elevations in phospho-
histone 3 positive cells were observed after irradiation
in pLKO.1 or shCDK4 cells (Table 4). This demonstrates
that CDK4 silencing does not radiosensitize cells by
causing accumulation of cells in mitosis.
Downregulation of CDK4 does not alter rates of DNA
break repair
To establish whether increased DNA repair is respon-
sible for radiation resistance, we measured DNA breaks
by detecting γ-H2AX foci. H2A.X is a variant histone
which is phosphorylated on Ser139 (γ-H2AX) by ATM,
ATR, or DNA PK at sites of DNA damage to recruit DNA
repair enzymes, thus representing an important mark of
DNA breaks [69-71]. This mark is one of the most sensi-
tive ways to detect active DNA repair foci [70,72]. In-
creased frequencies of γ-H2AX foci have been extensively
used to measure DNA damage by physical agents, onco-
genes, or inactive tumor suppressors [59,73,74]. Because
phosphorylated γ-H2AX is a major sensor of double
strand breaks, clearance of phospho-H2AX foci follow-
ing irradiation is also used as a measure of the repair of
that DNA damage [70,72]. Additional file 2 represents aeatment (shCDK4) groups
12 hr 24 hr
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Time (hr) after irradiation
Figure 3 Radiosensitivity imparted by downregulated CDK4 is not caused by altering cell cycle progression. Cells stably expressing
pLKO.1 or shCDK4 were unirradiated (basal), or irradiated at 2 Gy. Then, cells were collected at different times post-irradiation (0, 6, 12, & 24 hours)
stained with 7-AAD and were analyzed using flow cytometry to determine the cell cycle stages; 5000 cells per group were analyzed by the flow
cytometer. Flow cytometry and analysis was repeated three times. The columns represent the percentage of cells in the G1, S or G2/M phase and
presented as average±standard deviation. The G1/S and G2/M graphs were separated in order to make the G2/M data visible.
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(up to 48 hours post-irradiation), to establish whether
γ-H2AX foci were detected in non-irradiated cells (basal)
or following irradiation with 2 Gy. To measure the relative
repair capability of various cells, we irradiated cells withTable 4 Comparison of phospho-Histone 3 between control (p
Cell line Vector 0 Gy
Mean* std P-value† M
MCF10A pLKO.1 1.229 0.530
0.145
1
shCDK4 2.001 0.961 1
MDA-MB-468 pLKO.1 0.476 0.555
0.462
0
shCDK4 0.509 0.077 0




* Mean (standard deviation) of % of phospho-Histone 3 positive cells.
† P-value is for comparing in the mean between control and treatment groups in e2 Gy and detected γ-H2AX foci at different time points
post-irradiation. γ-H2AX foci were clearly detectable
upon irradiation (Additional file 2A). Regardless of the
cell line, the percentage of γ-H2AX foci decreased grad-
ually post-irradiation in all groups and reached basalLKO.1) and treatment (shCDK4) groups
2 Gy 4 Gy
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ach irradiation dosage.
Hagen et al. Cell Division 2013, 8:10 Page 7 of 17
http://www.celldiv.com/content/8/1/10levels by 24 hours. These baseline levels were maintained
48 hours post-irradiation. The γ-H2AX results obtained
by immunocytochemistry were independently investi-
gated in MCF10A, MDA-MB-231, and MDA-MB-468
cells using flow cytometry. This assay confirmed that no
significant differences existed between control and cells
silenced for CDK4 (Table 5). The experiments indicate
that the double stranded DNA repair capacity of all cells
analyzed in this study was intact.Irradiated breast cancer cell lines silenced for CDK4
display increased frequencies of apoptosis
Another mechanism that can explain the radiosensitization
of cells after CDK4 silencing is that its loss potentially
enhances frequencies of apoptosis. A pilot experiment
established the window of maximal apoptosis following
irradiation. Cell lines were either non-irradiated (basal),
or received a single dose (2 Gy) of radiation and were
collected at different times post-irradiation (0, 6, 12, 24
and 48 hours). Commitment to apoptosis was detected
by immunocytochemistry against the apoptotic effector
cleaved caspase-3 [75] (Figure 4A). This experiment re-
vealed a gradual increase in the percentage of apoptotic
cells, which became maximal at 48 hours (Additional
file 3). Silencing of CDK4 caused elevation in apoptosis
following irradiation in all cell lines tested, while knock-
down of CDK2 did not lead to any changes in frequen-
cies of apoptosis. Based on the results from the initial
experiment, cells were irradiated with 0, 2, and 4 Gy, and
analyzed 48 hours post-irradiation. Those experiments
confirmed a significant elevation of apoptosis in cells
silenced for CDK4 (Figure 4B). While MCF10A cells si-
lenced for CDK4 displayed a significant proportion of
caspase-3-positive cells under non-irradiated and with
2 Gy radiation, MDA-MB-468 cells silenced for CDK4
displayed a significant elevation in apoptosis only when
irradiated at 2 and 4 Gy. Even though the proportion of
apoptotic cells in MDA-MB-231 silenced for CDK4 wereTable 5 Comparison of γ-H2AX between control (pLKO.1) and
Cell line Vector 6 hr
Mean* std P-value† M
MCF10A pLKO.1 3.964 1.839
0.4621
3
shCDK4 2.803 2.216 1
MDA-MB-468 pLKO.1 2.148 1.176
0.8272
1
shCDK4 1.660 2.104 1
MDA-MB-231 pLKO.1 2.518 0.443
0.4119
3
shCDK4 3.710 2.273 3
* Mean (standard deviation) of the fold change to no radiation.
† P-value is for comparing in the mean fold change no radiation between control ahigher than controls in the basal and the 4 Gy groups, they
did not reach statistical significance.
To establish whether the increases in apoptosis caused
by radiation in cells silenced for CDK4 could be detected
with an independent apoptosis marker, cells were subjected
to Western blots using cleaved PARP (Figure 4C). In ac-
cordance with cleaved caspase-3 immunocytochemisty,
higher levels of cleaved PARP were detected in MCF10A
(6 to 11 fold changes) cells silenced for CDK4 compared
to vector control. Consistent with the small increases in
apoptosis with cleaved caspase-3, cleaved PARP levels
were slightly elevated in MDA-MB-231 silenced for CDK4
relative to pLKO.1 controls. Likewise, we detected slightly
elevated cleaved PARP levels in MDA-MB-468 shCDK4
cells irradiated with 2Gy relative to MDA-MB-468 pLKO.1
cells. In contrast, no difference was found in cleaved
PARP between MDA-MB-468 shCDK4 and MDA-MB-
468 pLKO.1 cells upon irradiation with 4 Gy.
To establish whether radiosensitization also occurred
through autophagy, we probed Western blots with an
antibody against LC3A/3B. In MCF10A cells, only the
lower band, which is the indicator of autophagy, was
detected with no great difference among samples. Both in-
active and active bands were observed in MDA-MB-231
and MDA-MB-468 cells, again with no great differences
among samples (Additional file 4A). Finally, to investi-
gate if the CDK4/6 kinase inhibitor, PD0332991, has a
similar effect on inducing apoptosis or autophagy, MCF10A,
MDA-MB-231 and MDA-MB-468 cells were treated at
their respective IC50s [64] of 100 nM, 500 nM, and 1000 nM
PD0332991, irradiated after 24 hours, and analyzed after
48 hours for cleaved PARP (Figure 4D). Unlike bio-
logical knockdown, levels of cleaved PARP did not in-
crease in MCF10A pLKO.1 cells treated with PD0332991.
Instead, high levels of cleaved PARP (2 to 3 fold) were
detected in MDA-MB-468 pLKO.1 cells treated with
PD0332991 compared to untreated cells. Again, LC3A/3B
levels were not changed greatly among any of the cell
lines, and did not change in the presence or absence oftreatment (shCDK4) groups
12 hr 24 hr






























































































































Figure 4 Irradiated breast cancer cell lines knocked down for CDK4 display increased frequencies of apoptosis. (A) Cells stably
expressing pLKO.1, shCDK2 or shCDK4 were unirradiated (basal), irradiated at 2 or 4 Gy. Cells were fixed at 48 hours post-irradiation. Cells were
subjected to immunostaining with anti-cleaved caspase-3 antibody (arrows), and an Alexa Fluor 488 secondary antibody; DNA was counter-
stained with DAPI. Pictures were collected at 20× magnification. (B) The number of cells positively stained with cleaved caspase-3 were counted
in a population of at least 287 cells and the results are shown as the proportion of positive cells between treatment and control groups. The
experiments were repeated 6 times. Statistical significance was calculated by a Chi-square/Fisher exact test (*=p≤0.05; **=p≤0.01). (C) Cells stably
expressing pLKO.1, or shCDK4 were unirradiated (0), irradiated at 2 or 4 Gy. Protein lysates were prepared 48 hours later and were subjected to
Western blot with anti-cleaved PARP antibody. β-actin was used as a loading control. (D) The CDK4/6 inhibitor PD0332991 was added to cells
stably expressing pLKO.1 (100 nM, 500 nM and 1000 nM for MCF10A, MDA-MB-231 and MDA-MB-468, respectively) and unirradiated (0), irradiated
at 2 or 4 Gy. Protein lysates were prepared 48 hours later and were subjected to Western blot with anti-cleaved PARP antibody. β-actin was used
as a loading control. Levels were normalized based on β-actin, and are indicated as fold-induction relative to non-irradiated pLKO.1 controls.
Hagen et al. Cell Division 2013, 8:10 Page 8 of 17
http://www.celldiv.com/content/8/1/10CDK4 (Additional file 4B). These results demonstrate
that knockdown of CDK4 and chemical inhibition of
CDK4/CDK6 lead to different outcomes, as the inhibitor
is protective of apoptosis in irradiated MCF10A and
MDA-MB-231 cells, while promoting apoptosis in MDA-
MB-468 cells. Overall, the results also demonstrate that
the primary mechanism of cell death in this system is
through apoptosis and not autophagy.Knockdown of CDK4 results in reduced phosphorylation
of BAD (ser136) and upregulation of protein phosphatase
type 2A (PP2A)
To assess why cells knocked down for CDK4 are prone
to apoptosis upon irradiation, we performed a screen of
various Bcl family members, with antibodies against the
phosphorylated forms of those proteins, as well as total
protein levels (Figure 5A). The lysates were obtained
AB
Figure 5 Downregulation of Cdk4 results in impaired
phosphorylation of BAD (ser136) and upregulation of protein
phosphatase type 2A (PP2A). Cells stably expressing pLKO.1 or
shCDK4 were irradiated at 2 Gy. Protein lysates were then prepared
at different times (0, 0.5, 1 & 2 hours) post-irradiation and were
immunoblotted with anti-Bad(ser136), anti-Mcl-1(ser159/thr163) and
anti-Bcl-2(ser70) antibodies, and their counterparts detecting total
levels of those proteins. (B) The levels of PP2A and PP2B were
further determined by immunoblotting with anti-PP2A and anti-PP2B
antibodies. Cells transfected with pLKO.1 were used as control. The
β-actin controls for (B) is the same as for (A).
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inhibits phosphatase 1, 2A and 2B; the limitation of such
method is that it increases the basal levels of most serine/
threonine phosphorylation in cells. This method has been
successfully used to detect phosphorylation of CDK2 or
CDK4 targets, including NPM [73,76,77]. There were no
significant changes in the levels of Bcl-2 (ser70) or Mcl-1
(ser159/thr163), or in the total levels of those proteins.
However, lower levels of phospho-Bad (ser136) were ob-
served in all irradiated ER-PR-HER2- cells expressing
shCDK4, while MCF10A cells had elevated levels of
phospho-Bad (ser136). Bad is a proapoptotic member of
the Bcl-2 family that promotes cell death by displacingBax from binding to Bcl-2 and Bcl-xL [78]. Phosphoryl-
ation of Bad at ser112 or ser136 via AKT inhibits the
apoptotic activity of Bad by promoting binding of Bad
to 14-3-3 proteins to prevent an association between
Bad with Bcl-2 and Bcl-xl [79]. The dephosphorylation
of Bad is mainly accomplished by various protein phos-
phatases [80-82]. We speculated that Bad ser136 was
being dephosphorylated through the increased activity
and/or levels of a phosphatase. It has been reported that
phospho-ser136 is more efficiently hydrolyzed by PP1?
and PP2A relative to PP2B and PP2C [82]. To find out
what is responsible for the dephosphorylation of Bad at
ser136, we detected the relative protein levels of the
protein phosphatases PP1α, PP2A, and PP2B. As shown
in Figure 5B, the basal levels of PP2A at time 0 were
immediately upregulated in MCF10A and MDA-MB-231
cells lacking CDK4 upon irradiation, and the levels
remained upregulated. As for MDA-MB-468 cells, the
levels of PP2A increased gradually following irradiation.
These experiments suggested that downregulation of CDK4
lead to increases in PP2A, which dephosphorylates
phospho-Bad in ser136.
Silencing the catalytic subunit of PP2A does not lead to
increased PARP cleavage in irradiated cells silenced for CDK4
To investigate whether silencing of PP2A reverses apop-
tosis in irradiated cells silenced for CDK4, the PP2A
catalytic unit was knocked down using siRNAs (Figure 6).
PP2A knock down was efficient in MDA-MB-231 (70%)
and MDA-MB-468 cells (50%) and irradiation further
decreased PP2A level in both negative control (30% less
compared to nonirradiated) and cells silenced for PP2Ac
(40-60% less compared to nonirradiated control). Over-
all, silencing PP2A did not change upregulated cleaved
PARP levels in MDA-MB-468 shCDK4. On the other
hand, it elevated cleaved PARP in MDA-MB-231 shCDK4
cells level compared to the negative controls. Knockdown
PP2A in MCF10A cells silenced for CDK4 under the
same conditions was not successful. The autophagy marker
LC3A/3B levels were not changed greatly among cell lines
and samples (Additional file 4C). This data indicates that
downregulation of PP2A does not reverse apoptosis in cells
knocked down for CDK4. We conclude that apoptosis
in irradiated cells silenced for CDK4 does not involve
the PP2A catalytic subunit.
Discussion
The G1 phase CDKs, (CDK2, CDK4, and CDK6) display
specific functions in terms of development and redundant
functions in terms of cell cycle regulation [23,24,83]. The
redundant nature of the G1 phase CDKs is best illus-
trated by work showing that cells can proliferate in the
absence of CDK2 and CDK4, and that CDK1 activity is
required for cell cycle progression [84,85]. However,
Figure 6 Silencing PP2A does not change cleaved PARP level in Cdk4 silencing cells. A cocktail of siRNAs targeting the PP2A catalytic unit
was transiently transfected into cells stably expressing shCDK4 and cells were irradiated at 0, 2 and 4 Gy after 48 hours transfection. Protein
lysates were then prepared at 48 hours post-irradiation and were immunoblotted with PP2A, cleaved PARP. β-actin was used as a loading control.
Protein levels were normalized based on β-actin, and are indicated as fold-induction relative to scrambled siRNA controls.
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[86]. Another important function of the CDKs is in
DNA repair. Specifically, cyclin D1, CDK4 [58,59,87],
cyclin A1, and CDK2 have been implicated in DNA repair
[88-92]. In fact, the activities of all CDKs are required for
efficient DNA repair [93]. Even though CDK2 and CDK4
are largely dispensable in the entry and progression
through S phase, they are important mediators of mam-
mary tumorigenesis in mice, as ablation of either CDK2
or CDK4 can prevent mouse mammary tumorigenesis
triggered by HER2/Neu [94,95]. Also, CDK2 and CDK4
can differentially mediate centrosome amplification de-
pending on the oncogenic or cellular context [96]. While
cyclin D1/CDK4 specifically mediates centrosome amplifi-
cation triggered by H-RasG12D, H-RasG12D&c-Myc [97],
and in HER2+ breast cancer cells [76], silencing of cyclin
E or CDK2 have no impact on centrosome amplification
in the HER2/Ras systems. In contrast, both CDK2 and
CDK4 mediate centrosome amplification and chromo-
some instability in p53 deficient cells [73].
Overall, the ability of CDK2 and CDK4 to mediate
various malignant phenotypes that play important roles
in cancer biogenesis has prompted the development of
CDK2 or CDK4 specific inhibitors. Those inhibitors have
proven to be effective in a variety of breast cancer cell
lines. For example, ER+ luminal cells that overexpress
cyclin D1 and Rb and display downregulated p16 respond
well to cell cycle inhibition by the CDK4/CDK6 specific
inhibitor PD-0332991, while non-luminal/basal cells are
refractive to growth inhibition [64]. It has been reported
that the Rb status dictates the early responses to that in-
hibitor [98]. Even though the CDK4/CDK6 inhibitor has
shown promise in preclinical trials, cells acquire resist-
ance through the upregulation of CDK2 activity [98]. A
major limitation of PD-0332991 is that while it is effective
in extinguishing mammary tumors, its ability to block the
cell cycle interferes with chemotherapy [99,100].In the present study, we addressed whether the G1/S
cell cycle regulatory machinery influences radioresistance
in MCF10A, ER-PR-HER2-, and ER-PR-HER2+ cells.
There is a precedent for the role of ectopic CDK2 and
CDK4 activities in imparting resistance or sensitivity to
radiotherapy. For example, knockdown of cyclin E
synergizes with doxorubicin to enhance radioresistance
in breast cancer cells lines [101]. Induction of cyclin A
has previously been observed in cells treated with UV or
irradiation [91,102]. Cyclin A null cells are radiosensi-
tive and display impaired double strand break repair;
cyclin A/CDK2 is involved in DNA repair following ir-
radiation by phosphorylating KU-70 [91].
Various mechanisms have been postulated to explain
how cyclin D1/CDK4 leads to radioresistance or radio-
sensitivity of various cells. Inducible expression of cyclin
D1 in MCF7 breast cancer cells leads to radiosensitivity
through activation of the p53 pathway [60]. Low dose
irradiation promotes the free, cytoplasmic cyclin D1 ac-
cumulation in human keratinocytes, correlating with
radioresistance; in this context, low level radiation dis-
rupted the interaction of cyclin D1 with 14-3-3ζ [55].
Cytoplasmic cyclin D1 then interacts with Bax, sup-
pressing the ability of Bax to induce apoptosis. In another
example, long term fractionated irradiation of the human
cancer cell lines HepG2 and HeLa induced radioresistance
[59]. This radioresistance correlated with upregulation of
cyclin D1 due to the stabilization of cyclin D1 by preven-
tion of its proteolysis, achieved by the DNA PK/AKT/
GSK3β pathway. In addition, they first proposed that
ectopic expression of cyclin D1 leads to increased
radioresistance in breast cancer cells by enhancing DNA
repair in the radioresistant cells, as downregulation of
cyclin D1 in this system abrogated enhanced DNA repair,
resulting in radiosensitivity. This group showed using chem-
ical inhibitors that cyclin D1 dependent radioresistance is
reversed by AKT or CDK4 chemical inhibitors. A recent
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in enhanced DNA repair and radioresistance [58]. This
report postulates that cyclin D1 promotes DNA repair
by interacting with RAD51 within DNA repair foci; this
interaction is promoted by radiation.
Our studies demonstrate that knockdown of CDK4
acts as a potent radiosensitizer, independently of the breast
cancer molecular subtype. In our studies, we tested whether
radiosensitization was a consequence of cell cycle inhibition
by silenced CDK4, altered DNA break repair, or through
the activation of an apoptotic program. We used various
assays to show that knockdown of CDK4 did not influ-
ence the cell cycle of non-irradiated or irradiated cells.
This is consistent with our previous observations that in
MCF10A cells expressing control pLKO.1, H-RasG12V,
H-RasG12V&c-Myc, or in HER2+ breast cancer cells,
knockdown of CDK4 does not greatly influence DNA
replication or cell cycle progression [76,97]. This is also
consistent with our data showing that ablation of CDK4
does not alter the cell cycle of p53−/− mouse embryonic
fibroblasts [73]. In contrast, co-inhibition of CDK4 and
CDK6 using a chemical inhibitor interferes with the
cell cycle, leading to protection against chemotherapy
[99,100]. Our studies conducted with the PD0332991
CDK4/CDK6 inhibitor revealed a similar story, as treat-
ment of MCF10A or MDA-MB-231 protected against
radiation-induced apoptosis. This is contrary to our
studies revealing that knockdown of CDK4 synergizes
with radiation to induce apoptosis in breast cancer cells
and MCF10A controls. The only cell in which radiation
synergized with inhibition of CDK4/CDK6 was MDA-
MB-468, a cell that is insensitive to growth inhibition
by PD0332991. However, we do not think that insensi-
tivity to growth inhibition is the sole cause of the sensi-
tivity to apoptosis triggered by PD0332991 treatment,
as we treated all cell lines exactly at IC50 to prevent
complete growth inhibition. One potential explanation
for the differences between knockdown of CDK4 and
inhibition with PD0332991 is that while the chemical
inhibits CDK4/CDK6 activity, the shCDK4 may disrupt
the protein:protein interactions of CDK4 with cyclin D,
p21, p27, p15, p16, p18 and p19, leading to modulation
of the activities of other CDKs.
In contrast to studies showing that increased cyclin
D1 activity results in radioresistance through increasing
cellular DNA repair capacity, all breast cancer cells tested
in this study efficiently repaired DNA breaks irrespective
of CDK4 levels, as indicated by the efficient clearance of
H2AX foci after radiation. A recent study is consistent
with our results, as chemical inhibition of CDK4 and
CDK6 in breast cancer cells did not influence double-
strand break repair after irradiation [99]. We speculate
that the differences between cyclin D1 and CDK4/CDK6
inhibition in relation to DNA repair is because cyclin D1displays functions that are independent of CDK4. For
example, it can bind the promoters of genes involved in
chromosome instability [103].
The presence of increased levels of cleaved caspase-3
and of cleaved PARP in all irradiated cells down regu-
lated for CDK4 indicated that apoptosis was a significant
driver of radioresistance in mammary epithelial and breast
cancer cells. Although apoptosis is high in unirradiated
MCF10A cells silenced for CDK4, levels of apoptosis
rise significantly in those and in the breast cancer cells
silenced for CDK4 upon irradiation. This suggests syn-
ergy between downregulation of CDK4 and irradiation
in regards to apoptosis. To establish how absence of
CDK4 cooperates with radiation to enhance cell death,
we screened various Bcl family members. No changes in
the levels of phosphorylation of the antiapoptotic mem-
bers Bcl2 or Mcl1 were observed in the cells. In con-
trast, levels of phosphorylated Bad ser136 were sharply
diminished Even though dephosphorylation of Bad in
serine 136 is associated with apoptosis, we observe in-
creased phosphorylation in irradiated shCDK4 MCF10A
cells. The regulation of apoptosis is complex, involving
various protein/protein interactions, as well as the post-
translational modification of numerous proteins. Fur-
ther studies must be performed in order to establish
why MCF10A cells silenced for CDK4 display phosphory-
lated Bad Ser 136, and still apoptose. Bad ser136 phos-
phorylation is reversed by various phosphatases, including
PP2A and PP1α [81,82]. In fact, silencing of CDK4
resulted in higher levels of PP2A, suggesting that it spe-
cifically dephosphorylates Bad ser136 upon irradiation
PP2A is a protein complex with many cellular functions,
including the regulation of apoptotic and mitogenic
pathways [104-106], as well as the modulation of DNA
repair [107]. Inhibition of PP2A by DNA tumor viruses
is tightly linked to cellular transformation [108]. Also,
the dephosphorylation of Bcl2 by PP2A promotes its
anti-apoptotic activity; this event may enhance Bcl2’s
oncogenic potential [109]. In wide contrast, PP2A’s
proapoptotic activities have been mapped to its ability
to dephosphorylate Bad [81,82] and Bax [110]. We did
not observe significant dephosphorylation of Bcl2 in any
of the cell lines, suggesting that upregulation of PP2A in
breast cancer cells exclusively dephosphorylates Bad
ser136 without significantly affecting other Bcl family
members. Thus, our observation that downregulation of
CDK4 resulted in decreased phosphorylation of Bad
ser136 suggests that this event is primarily responsible
for apoptosis and radioresistance. Additional experiments
are required to address how CDK4 regulates PP2A levels;
that regulation may result from increased protein stability,
increased degradation, or enhanced de-repression of E2F
target genes upon CDK4 silencing. Another important
future area of exploration is whether and how the
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conjunction with radiation is rooted in Rb/E2F dependent
transcription.
Unfortunately, we were unable to show that ectopic
expression of PP2Ac radiosensitizes breast cancer cells,
or that its inhibition modulates radiation induced apop-
tosis in breast cancer cells. We conclude that apoptosis
in cells knocked down for CDK4 is independent of PP2A.
Further experiments are required to establish pathways
signaling apoptosis in irradiated breast cancer cells
knocked down for CDK4.
Conclusion
We conclude that stable knockdown of CDK4 enhances
the effects of radiation by enhancing apoptotic pathways.
This result has implications for future therapies, as pa-
tients can be treated with radiation or chemotherapeutic
agents and with doses of CDK4/CDK6 inhibitors that do
not block the cell cycle. In that scenario, suppression of
CDK4/CDK6 activity would allow cell cycle progression,
while synergizing with radiation to increase cell death.
Materials and methods
Cell culture
A human mammary epithelial cell line (MCF10A) and
breast cancer cell lines (ER-PR-HER2-:HCC1806, HS578,
MDA-MB-231, MDA-MB-468; ER-PR-HER2+: SKBR3
and HCC1954), were purchased from ATCC (Rockville,
MD), or obtained through collaborators. The molecular
markers and various other characteristics of the breast
cancer cells used in this study have been previously de-
scribed [111]. HCC1806, HCC1954, and SKBR3 cells
were cultured in RPMI supplemented with 10% fetal bovine
serum (FBS). HS578, MDA-MB-231 and MDA-MB-468
cells were cultured in DMEM supplemented with 10% FBS.
MCF10A cells were cultured in DMEM/F12 supple-
mented 10% FBS, 20 ng/ml EGF, 100 ng/ml cholera toxin,
0.01mg/ml insulin, and 500 ng/ml hydrocortisone. All cell
lines were cultured at 37°C in a humidified atmosphere
(5% CO2).
Colony forming assay
Two thousand five hundred cells were plated per well in
a 6-well culture plate or one thousand cells were plated
per well in a 12-well cell culture plate (Day 0) in triplicates.
After 24 hours (Day 1), cells were irradiated at a dose of 0,
1, 2, 4, 6, or 8Gy in an X-RAD 320 irradiator (Precision
X-Ray, CA). After an average of 8 days, cells were fixed
with 75% ethanol and stained with 1% crystal violet, and
colonies containing more than 50 cells (established by
microscopy) were counted manually. Plating efficiency
was calculated by dividing the number of colonies in the
unirradiated group divided by the number of colonies
plated and multiplying by 100.Lentiviral shRNA transduction
The shRNA constructs against CDK2 or CDK4 were
cloned into the lentiviral vector pLKO.1, which are com-
mercially available from OPEN Biosystems. Lentiviral in-
fections were done as described in our publications [97].
Briefly, cells were plated in regular medium at 50% con-
fluence on day 1. This was followed by changing into
medium containing 5 μg/ml polybrene and infection of
cells by adding undiluted shRNA lentiviral particles to
the culture on day 2. Stable clones expressing the shRNA
were obtained by splitting cells 1:5 and culturing in
medium containing puromycin.
Immunocytochemistry assays
Immunofluorescence was performed by following our
published protocols [73,97]. Cells were plated at 4×104
per well into two-well tissue culture chamber slides and
received 2 Gy irradiation after cells attached. Cells were
then fixed in cold 4% paraformaldehyde at different
times postirradiation (from 0 to 48 hr), washed in PBS,
permeabilized in a 1% NP-40–PBS solution, and blocked
in 10% goat serum. Commitment to apoptosis was detected
by using an antibody against cleaved caspase-3 (9661, Cell
Signaling). DNA breaks were detected using an antibody
against phosphorylated histone 2A variant X (γ-H2AX)
(ab2893, Abcam). Cell proliferation was examined using an
antibody against Ki-67 (ab15580, Abcam). The BrdU assay
was used to detect cells in S phase and was done by pulsing
cells with 20 μM BrdU (51-7581KZ; BD Pharmingen)
30 minutes before harvest and detecting with an anti-
BrdU antibody (NA61; Calbiochem). To detect mitosis,
cells were plated at 1×104 per well into four-well tissue
culture chamber slides and received 0, 2 and 4 Gy irradi-
ation 24 hours after plating and incubated 48 hours and
phosphor-histone 3 (Ser 28, 9713, Cell Signaling) anti-
body was used to detect mitosis. Secondary antibodies
are conjugated with Alexa Fluor 555 or Alexa Fluor 488.
Cells were counterstained with DAPI. Frequencies of
the various phenotypes are done by counting the num-
ber of antigen-positive cells divided by the total number
of cells; unless otherwise indicated, we count at least 200
cells per group. For mitosis, over 300 cells per group were
counted.
Western blots
Western blotting was performed according to published
protocols [73,97]. Protein lysates were obtained by incu-
bating cells in lysis buffer (50 mM HEPES, 250 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP-40, 10% glycerol)
containing protease inhibitors (04693124001, Roche) for
30min at 4°C. Calyculin phosphatase inhibitor (Millipore
19-139v) was added to the culture medium at a concentra-
tion of 100 nM, 30 minutes before harvest for the detec-
tion of phosphorylated proteins. Samples were denatured
Hagen et al. Cell Division 2013, 8:10 Page 13 of 17
http://www.celldiv.com/content/8/1/10at 95°C for 5min in sodium dodecyl sulfate (SDS) sample
buffer, resolved by SDS polyacrylamide gel electrophoresis
and transferred to polyvinylidene difluoride membranes
(Bio-Rad). The blots were incubated in blocking buffer
(5% nonfat dry milk in 1X Tris-buffered saline plus 0.1%
Tween 20 [TBS-T]) for 1hr and were then probed over-
night at 4°C with the primary antibodies. The blots were
then rinsed in 1X TBS-T and incubated with the appro-
priate horseradish peroxidase conjugated secondary
antibodies at room temperature. The blots were then
rinsed in 1X TBS-T and the antibody-antigen complex
was visualized using Lumigen TMA-6 (RPN2135v1 and
RPN2135v2; GE Healthcare).Antibodies and inhibitors
The antibodies used in the various Western blotting ex-
periments were as follows: CDK2 (sc-163, Santa Cruz),
CDK4 (2906, Cell Signaling), p21Waf1 (sc-397, Santa Cruz),
p27Kip1 (sc-528, Santa Cruz), β-actin (4970, Cell Signal-
ing), cyclin A (ab38, Abcam), cyclin D1 (2922, Cell Sig-
naling), cyclin E (sc-481, Santa Cruz), Phospho-Bcl-2
ser70 (2827, Cell Signaling), Bcl-2 (OP60, Calbiochem),
Phospho-Mcl ser159/thr163 (4579, Cell Signaling), Mcl-1
(sc-819, Santa Cruz), Phospho-Bad ser136 (06–846, Upstate),
Bad (1541–1, Epitomic), Phospho-AKT Ser 473 (Cell Sig-
naling), PP1α (2582, Cell Signaling), PP2A (2259, Cell Signal-
ing) and PP2B (2614, Cell Signaling), cleaved PARP (Asp214,
5625, Cell Signaling). The CDK4/6 inhibitor PD0332991
(Axon1505) was purchased from Axon Medchem. When
indicated, ImageJ software was used to quantify protein
levels of Western blots (NIH).Flow cytometry
Cells were irradiated at 2 Gy, pulsed with BrdU (added at
a final concentration of 10 μM 30min prior to harvest)
and harvested at various time points (6, 12, and 24 hours).
Timepoints were chosen based on our preliminary and
supplementary data. A unirradiated control was also col-
lected. 1×106 cells were transferred to 5ml round bottom
tubes (352235, BD), and cell staining was performed
according to the protocol included with the “Apoptosis,
DNA damage and Cell Proliferation kit” (562253, BD)
or stained with 7-AAD (559925, BD Biosciences). BrdU
was detected using PerCP-Cy™5.5 Mouse Anti-BrdU
(51–9007682, BD), PARP cleavage was identified with
PE Mouse Anti-Cleaved PARP (Asp214) Antibody (51–
9007684, BD) and γH2AX was distinguished using Alexa
Fluor® 647 Mouse Anti-H2AX (pS139) (51–9007683, BD).
A LSRII flow cytometer (BD) was used to read each sam-
ple. Compensation was performed using Anti-Mouse Ig,
κ/Negative Control (FBS) Compensation Particles Set
(BD, 552843) and samples were analyzed using Flowjo
v7.6.5 and v10.4 (Tree Star).Statistical methods
For the colony forming assay, a dose response analysis
was conducted, in which the dose response relationship
was assumed to be the commonly used four parameter
logistic function [112]. The data was normalized relative
to the baseline dose level=0 Gy (no radiation), and the
percentage of control was used as the primary outcome
in the analysis. IC50, the radiation dose that is required
for 50% reduction from baseline dose level, was the par-
ameter of interest and compared accordingly. The higher
value of IC50, the higher the resistance. A proper data
transformation, Box- Cox transformation, [113] was ap-
plied to assure the fitted model meeting the statistical
assumptions. All data management and statistical ana-
lyses were done in R [114]. T-tests were done in Excel.
The statistical significance level of all tests was set at 0.05.
For the flow cytometry assays (DNA content and BrdU)
the data was aligned by the six-hour gates. The two mea-
surements (percentages of positive cells) per each run are
averaged at each time point and the averaged measure-
ment at each of 6 hours, 12 hours and 24 hours after radi-
ation is divided by the averaged measurement at baseline.
The mean percentage of the positive cells relative to no
radiation is used for analyses, named fold-change to no
radiation. The main goal of this data analysis is to compare
the fold change between control and treatment groups at
each time point, within each cell line, biomarker, and gate.
The fold change is compared between control group and
treatment group (pLKO.1 vs. shCDK4) at each time point
within each cell line, biomarker, and gate using ANOVA
(Analysis of Variance) to estimate the mean and standard
error for the fold change to non-radiation. For the cleaved
caspase-3 assay, observations (number of positive or nega-
tive cells) are combined within each radiation dose of 2Gy,
4 Gy or no radiation treated cells for each control group
and treatment group and then the Chi-square test or
Fisher’s exact test is used to compare the proportions of
positive and negative cells between treatment and control
groups. Analysis unit is a cell. The significance levels are
set at 0.05 for all tests. The SAS statistical package V9.3
(SAS Institute, Inc., Cary, North Carolina) is used for data
managements and analyses.
Ethical approval
No research on humans or animals were conducted. All
human cell lines were purchased from the publically
available American Type Culture Collection (ATCC), or
obtained through collaborators.
Additional files
Additional file 1: Radiosensitivity imparted by downregulated Cdk4
is not caused by impaired proliferation. (A) Cells stably expressing
control pLKO.1, shCDK2 or shCDK4 were unirradiated (Basal) or irradiated
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post-irradiation (0, 6, 12, 24, & 48 hours), and were subjected to
immunostaining with an anti-BrdU antibody, and an Alexa Fluor
secondary antibody. Nuclei were counter-stained with DAPI. The number
of cells positively stained with BrdU was counted in 200 cells per group,
and the results are shown as the average±standard deviation from two
independent experiments. (B) Cells stably expressing pLKO.1, shCDK2 or
shCDK4 were unirradiated (Basal), or irradiated at 2 Gy. Cells collected
from different time points (0, 6, 12, 24, & 48 hours) post-irradiation were
subjected to immunostaining with anti-Ki67 antibody, an Alexa Fluor
secondary and the DNA was counter-stained with DAPI. The number of
cells positively stained with Ki67 was counted in 200 cells per group, and
the results are shown as the average±standard deviation from two
experiments.
Additional file 2: Downregulation of Cdk4 does not alter rates of
DNA break repair. Non-infected cells and cells stably expressing pLKO.1,
shCDK2 or shCDK4 were irradiated at 2 Gy. The basal levels were
determined in unirradiated cells. Cells were fixed at different times (0, 6,
12, 24, & 48 hours) post-irradiation and were subjected to
immunostaining with anti-H2A.X antibody (γ-H2AX) and an Alexa Fluor
555 secondary antibody; DNA was counter-stained with DAPI (A). Blue
cells represent nuclei, while the red cells (arrows) represent cells
expressing γ-H2AX. Pictures were taken at a 65× magnification. (B) The
number of cells positively stained with γ-H2AX was counted in 200 cells per
group, and the results are shown as the average±standard deviation from
two experiments.
Additional file 3: Silencing of Cdk4 promotes apoptosis. Cells stably
expressing pLKO.1, shCDK2 or shCDK4 were irradiated at 2 Gy. The basal
levels were determined in unirradiated cells. Cells were fixed at different
times (0, 6, 12, 24, & 48 hours) post-irradiation and were subjected to
immunostaining with anti-cleaved caspase-3 antibody and an Alexa Fluor
555 secondary antibody; DNA was counter-stained with DAPI. The number
of cells positively stained with cleaved caspase-3 was counted in 200 cells
per group, and the results are shown as the average±standard deviation
from two experiments.
Additional file 4: CDK4 silencing did not change degree of
autophagy. (A) Cells stably expressing control pLKO.1 and shCDK4 were
irradiated at 0, 2 and 4 Gy. Protein lysates were prepared after 48 hours
post irradiation and were subjected to Western blot with an anti-LC3A/3B
antibody. β-actin was used as a loading control. (B) Cells stably expressing
control pLKO.1 were treated with the CDK4/6 inhibitor PD0332991 and
irradiated at 0, 2 and 4 Gy. Protein lysates were prepared after 48 hours post
irradiation and were subjected to Western blot with an anti-LC3A/3B
antibody. β-actin was used as a loading control. (C) Cells stably expressing
shCDK4 was transfected with siRNA targeting the PP2A catalytic unit for
48 hours and irradiated at 0, 2 and 4 Gy. Protein lysates were prepared
after 48 hours post irradiation and were subjected to Western blot with
an anti-LC3A/3B antibody. β-actin was used as a loading control.
Abbreviations
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